2024
A simple, field-applicable method to increase the infectivity of wild isolates of Plasmodium falciparum to mosquito vectors
Ouattara S, Hien D, Nao E, Paré P, Guissou E, Cohuet A, Morlais I, Yerbanga R, Dabiré K, Ouédraogo J, Mouline K, Lefèvre T. A simple, field-applicable method to increase the infectivity of wild isolates of Plasmodium falciparum to mosquito vectors. Malaria Journal 2024, 23: 135. PMID: 38711028, PMCID: PMC11075210, DOI: 10.1186/s12936-024-04969-0.Peer-Reviewed Original ResearchConceptsDirect membrane feeding assaysGametocyte densityHuman-to-mosquito transmissionDonor bloodLow gametocyte densitiesMembrane feeding assaysPlasmodium falciparum gametocytesTransmission-blocking interventionsWhole bloodInfection rateFalciparum gametocytesInfectious reservoirNaive serumAsymptomatic individualsMosquito infectionHuman donorsRemoval of plasmaEndemic countriesSerumPlasmodiumParasite isolatesInfectionBlood treatmentGametocytesPlasma volumeSafety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Datoo M, Dicko A, Tinto H, Ouédraogo J, Hamaluba M, Olotu A, Beaumont E, Lopez F, Natama H, Weston S, Chemba M, Compaore Y, Issiaka D, Salou D, Some A, Omenda S, Lawrie A, Bejon P, Rao H, Chandramohan D, Roberts R, Bharati S, Stockdale L, Gairola S, Greenwood B, Ewer K, Bradley J, Kulkarni P, Shaligram U, Hill A, Group R, Mahamar A, Sanogo K, Sidibe Y, Diarra K, Samassekou M, Attaher O, Tapily A, Diallo M, Dicko O, Kaya M, Maguiraga S, Sankare Y, Yalcouye H, Diarra S, Niambele S, Thera I, Sagara I, Sylla M, Dolo A, Misidai N, Simando S, Msami H, Juma O, Gutapaka N, Paul R, Mswata S, Sasamalo I, Johaness K, Sultan M, Alexander A, Kimaro I, Lwanga K, Mtungwe M, Khamis K, Rugarabam L, Kalinga W, Mohammed M, Kamange J, Msangi J, Mwaijande B, Mtaka I, Mhapa M, Mlaganile T, Mbaga T, Yerbanga R, Samtouma W, Sienou A, Kabre Z, Ouedraogo W, Yarbanga G, Zongo I, Savadogo H, Sanon J, Compaore J, Kere I, Yoni F, Sanre T, Ouattara S, Provstgaard-Morys S, Woods D, Snow R, Amek N, Ngetsa C, Ochola-Oyier L, Musyoki J, Munene M, Mumba N, Adetifa U, Muiruri C, Mwawaka J, Mwaganyuma M, Ndichu M, Weya J, Njogu K, Grant J, Webster J, Lakhkar A, Ido N, Traore O, Tahita M, Bonko M, Rouamba T, Ouedraogo D, Soma R, Millogo A, Ouedraogo E, Sorgho F, Konate F, Valea I. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. The Lancet 2024, 403: 533-544. PMID: 38310910, DOI: 10.1016/s0140-6736(23)02511-4.Peer-Reviewed Original ResearchConceptsClinical malaria episodesPhase 3 trialMalaria episodesMonths age groupAdverse eventsVaccine efficacyClinical malariaMalaria vaccineDouble-blindMalaria transmissionControl vaccineAsn-Ala-Asn-ProAge groupsStandard sitesMonths of follow-upAfrican childrenPerennial malaria transmissionBurden of malariaSeasonal malaria transmissionMalaria transmission intensityPhase 2b trialInjection site painFrequent adverse eventsCo-primary endpointsVaccine-induced antibodies
2023
Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa.
Djimde M, Kayentao K, Tshiongo J, Fofana B, Arama C, Sirima S, Ouedraogo J, Beavogui A, Sagara I, Dicko A, Mens P, Schallig H, Djimde A. Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa. The Journal Of Infection In Developing Countries 2023, 17: 1337-1345. PMID: 37824364, DOI: 10.3855/jidc.17089.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyNormal neutrophil countsPolymorphonuclear neutrophilsDay 28Neutropenia groupPyronaridine-ArtesunateNeutrophil countNeutrophil levelsDifferent artemisinin-based combination therapiesRole of PMNsCombination therapy efficacyP. falciparum parasitemiaPositive blood smearPlasmodium falciparum parasitemiaLevels of neutrophilsAL armASAQ armProspective longitudinalRecurrent parasitemiaCombination therapyNeutrophil rateNeutropenia patientsNormal ratePatientsPathogen clearanceThe impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso
Guissou R, Amaratunga C, de Haan F, Tou F, Cheah P, Yerbanga R, Moors E, Dhorda M, Tindana P, Boon W, Dondorp A, Ouédraogo J. The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso. Malaria Journal 2023, 22: 269. PMID: 37705004, PMCID: PMC10498571, DOI: 10.1186/s12936-023-04705-0.Peer-Reviewed Original ResearchConceptsDepth interviewsGroup discussionsNational policy makersDrug marketBurkina FasoFocus group discussionsPolicy publicationsPublic policyCommunity membersFunding systemPolicy makersAfrican countriesPolicyAnti-malarial policyMarket characteristicsAnti-malarial marketInterviewsRepresentative sampleGrey literatureMarketFasoPerspectiveEmergenceTerms of availabilityDiscussionSeasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial
Dicko A, Ouedraogo J, Zongo I, Sagara I, Cairns M, Yerbanga R, Issiaka D, Zoungrana C, Sidibe Y, Tapily A, Nikièma F, Sompougdou F, Sanogo K, Kaya M, Yalcouye H, Dicko O, Diarra M, Diarra K, Thera I, Haro A, Sienou A, Traore S, Mahamar A, Dolo A, Kuepfer I, Snell P, Grant J, Webster J, Milligan P, Lee C, Ockenhouse C, Ofori-Anyinam O, Tinto H, Djimde A, Chandramohan D, Greenwood B. Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. The Lancet Infectious Diseases 2023, 24: 75-86. PMID: 37625434, DOI: 10.1016/s1473-3099(23)00368-7.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionPhase 3 trialClinical malariaAlone groupMalaria Vaccine InitiativeMalaria chemopreventionSeasonal vaccinationProtective efficacyCombined groupPATH Malaria Vaccine InitiativeGlobal Health TrialsPrimary trial endpointSeasonal malaria transmissionSingle intervention groupSupplementary Materials sectionBougouni DistrictCause deathModified intentionProtocol populationControl vaccineMalaria vaccinationMalarial anemiaSevere malariaBlood transfusionHospital admissionSeasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study
Roh M, Zongo I, Haro A, Huang L, Somé A, Yerbanga R, Conrad M, Wallender E, Legac J, Aweeka F, Ouédraogo J, Rosenthal P. Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study. The Journal Of Infectious Diseases 2023, 228: 926-935. PMID: 37221018, PMCID: PMC10547452, DOI: 10.1093/infdis/jiad172.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionDrug levelsMonths of ageOdds ratioHigh-level SP resistanceSP-AQCase-control studyConditional logistic regressionLow drug levelsPrevalence of mutationsDrug resistance markersCase-control designResistance markersIncident malariaParasitemic childrenMalaria chemopreventionAntimalarial resistanceChildren 6Health facilitiesSP resistanceChildren 3Malaria incidenceDrug resistanceMalariaLogistic regressionTracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study
Ehrlich H, Somé A, Bazié T, Ebou C, Dembélé E, Balma R, Goodwin J, Wade M, Bei A, Ouédraogo J, Foy B, Dabiré R, Parikh S. Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study. The Lancet Microbe 2023, 4: e461-e469. PMID: 37086737, PMCID: PMC10365133, DOI: 10.1016/s2666-5247(23)00063-0.Peer-Reviewed Original ResearchConceptsMosquito blood mealsAntimalarial drug resistanceSurvey 3Blood-fed mosquitoesBlood samplesSurvey 1Survey 2Blood mealDrug resistanceUltrasensitive quantitative PCRHuman blood samplesCross-sectional studyMargin of equivalenceStrong surveillance systemCross-sectional surveySupplementary Materials sectionMarker of clonalityPragmatic thresholdAntimalarial resistanceDrug susceptibilityInfectious diseasesPlasmodium falciparumNational InstituteTolerabilityMaterial sectionCost of introducing and delivering malaria vaccine (RTS,S/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso
Diawara H, Bocoum F, Dicko A, Levin A, Lee C, Koita F, Ouédraogo J, Guissou R, Yabré S, Traoré S, Morgan W, Pecenka C, Baral R. Cost of introducing and delivering malaria vaccine (RTS,S/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso. BMJ Global Health 2023, 8: e011316. PMID: 37068848, PMCID: PMC10111920, DOI: 10.1136/bmjgh-2022-011316.Peer-Reviewed Original ResearchConceptsVaccine deliverySeasonal vaccinationMalaria vaccineMalaria transmissionSeasonal malaria transmissionRoutine Expanded ProgrammeResource use dataRoutine EPINew vaccine introductionSeasonal malariaVaccine introductionMain cost driversHealth facilitiesExpanded ProgrammeVaccine priceVaccine rolloutMass campaignsService deliveryYoung childrenVaccinationCost consequencesBurkina FasoFinancial costsVaccineDelivery approach
2022
Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein
Lapidus S, Liu F, Casanovas-Massana A, Dai Y, Huck J, Lucas C, Klein J, Filler R, Strine M, Sy M, Deme A, Badiane A, Dieye B, Ndiaye I, Diedhiou Y, Mbaye A, Diagne C, Vigan-Womas I, Mbengue A, Sadio B, Diagne M, Moore A, Mangou K, Diallo F, Sene S, Pouye M, Faye R, Diouf B, Nery N, Costa F, Reis M, Muenker M, Hodson D, Mbarga Y, Katz B, Andrews J, Campbell M, Srivathsan A, Kamath K, Baum-Jones E, Faye O, Sall A, Vélez J, Cappello M, Wilson M, Ben-Mamoun C, Tedder R, McClure M, Cherepanov P, Somé F, Dabiré R, Moukoko C, Ouédraogo J, Boum Y, Shon J, Ndiaye D, Wisnewski A, Parikh S, Iwasaki A, Wilen C, Ko A, Ring A, Bei A. Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein. Scientific Reports 2022, 12: 22175. PMID: 36550362, PMCID: PMC9778468, DOI: 10.1038/s41598-022-26709-7.Peer-Reviewed Original ResearchConceptsCross-reactive antibodiesSARS-CoV-2Positive SARS-CoV-2 antibody resultsPositive SARS-CoV-2 antibodiesSARS-CoV-2 reactivitySARS-CoV-2 antibodiesAcute malaria infectionSpike proteinAntibody test resultsPre-pandemic samplesMalaria-endemic countriesPopulation-level immunityMalaria-endemic regionsSpike S1 subunitNon-endemic countriesSARS-CoV-2 spike proteinSARS-CoV-2 proteinsPopulation-level exposureCOVID-19 transmissionMalaria exposureFalse-positive resultsMalaria infectionDisease burdenPlasmodium infectionAntibody resultsSeasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study
Thompson H, Hogan A, Walker P, Winskill P, Zongo I, Sagara I, Tinto H, Ouedraogo J, Dicko A, Chandramohan D, Greenwood B, Cairns M, Ghani A. Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study. The Lancet Global Health 2022, 10: e1782-e1792. PMID: 36400084, DOI: 10.1016/s2214-109x(22)00416-8.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionSeasonal transmission settingsS vaccinationTransmission settingsTransmission seasonFull therapeutic coursePhase 3b trialSevere malaria outcomesUK Medical Research CouncilEstimates of casesDuration of protectionMalaria transmission intensityEntomological inoculation rateGreater absolute reductionMedical Research CouncilTransmission intensitySignificant additional protectionAge-based strategiesMalaria outcomesClinical malariaMalaria chemopreventionVaccination scheduleMalaria vaccineClinical incidenceClinical trialsPreventive small-quantity lipid-based nutrient supplements reduce severe wasting and severe stunting among young children: an individual participant data meta-analysis of randomized controlled trials
Dewey K, Arnold C, Wessells K, Prado E, Abbeddou S, Adu-Afarwuah S, Ali H, Arnold B, Ashorn P, Ashorn U, Ashraf S, Becquey E, Brown K, Christian P, Colford J, Dulience S, Fernald L, Galasso E, Hallamaa L, Hess S, Humphrey J, Huybregts L, Iannotti L, Jannat K, Lartey A, Le Port A, Leroy J, Luby S, Maleta K, Matias S, Mbuya M, Mridha M, Nkhoma M, Null C, Paul R, Okronipa H, Ouédraogo J, Pickering A, Prendergast A, Ruel M, Shaikh S, Weber A, Wolff P, Zongrone A, Stewart C. Preventive small-quantity lipid-based nutrient supplements reduce severe wasting and severe stunting among young children: an individual participant data meta-analysis of randomized controlled trials. American Journal Of Clinical Nutrition 2022, 116: 1314-1333. PMID: 36045000, DOI: 10.1093/ajcn/nqac232.Peer-Reviewed Original ResearchConceptsSmall-quantity lipid-based nutrient supplementsLipid-based nutrient supplementsSevere wastingIndividual participant dataParticipant dataPassive control armStudy-level characteristicsSevere stuntingMo of ageFixed-effects modelNutrient supplementsHealthy child growthControl armChildren 6Inclusion criteriaEffect modifiersPreventive interventionsChild wastingGreater burdenSubgroup estimatesWastingChild growthYoung childrenStuntingRelative reductionPrevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study
Beshir K, Muwanguzi J, Nader J, Mansukhani R, Traore A, Gamougam K, Ceesay S, Bazie T, Kolie F, Lamine M, Cairns M, Snell P, Scott S, Diallo A, Merle C, NDiaye J, Razafindralambo L, Moroso D, Ouedraogo J, Zongo I, Kessely H, Doumagoum D, Bojang K, Ceesay S, Loua K, Maiga H, Dicko A, Sagara I, Laminou I, Ogboi S, Eloike T, Milligan P, Sutherland C. Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. The Lancet Infectious Diseases 2022, 23: 361-370. PMID: 36328000, DOI: 10.1016/s1473-3099(22)00593-x.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionResistance-associated variantsParasite carriageSurvey-weighted prevalenceMalaria transmission seasonQuantitative PCRPrevalence ratiosP falciparumGenomic surveillance studyChemoprevention drugsBlood samplesSurveillance studyTransmission seasonChemopreventionPlasmodium falciparumAmodiaquinePrevalenceMDR1Variant haplotypeSequencing of isolatesSignificant reductionChildrenPyrimethamineCommunity surveyThe duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria chemoprevention versus either intervention given alone
Cairns M, Barry A, Zongo I, Sagara I, Yerbanga S, Diarra M, Zoungrana C, Issiaka D, Sienou A, Tapily A, Sanogo K, Kaya M, Traore S, Diarra K, Yalcouye H, Sidibe Y, Haro A, Thera I, Snell P, Grant J, Tinto H, Milligan P, Chandramohan D, Greenwood B, Dicko A, Ouedraogo J. The duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria chemoprevention versus either intervention given alone. BMC Medicine 2022, 20: 352. PMID: 36203149, PMCID: PMC9540742, DOI: 10.1186/s12916-022-02536-5.Peer-Reviewed Original ResearchConceptsDuration of protectionSeasonal malaria chemopreventionClinical malariaMalaria chemopreventionProtective efficacyDifferent vaccine delivery systemsFlexible parametric survival modelsMalaria transmission seasonOverall protective efficacyVaccine delivery systemChild clusteringBooster dosesSeasonal vaccinationMalaria vaccinationSevere malariaDelivery intervalParametric survival modelsCox regressionMalaria vaccinePrimary seriesRecent trialsIntervention groupConclusionsThe efficacyAS01ECox modelEthical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
Tindana P, Guissou R, Bolarinwa O, Tou F, de Haan F, Dhorda M, Dondorp A, Amaratunga C, Mokuolu O, Ouedraogo J, Cheah P. Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria. PLOS ONE 2022, 17: e0273249. PMID: 36083995, PMCID: PMC9462557, DOI: 10.1371/journal.pone.0273249.Peer-Reviewed Original ResearchConceptsTriple artemisinin-based combination therapiesArtemisinin-based combination therapyCombination therapyArtemisinin resistanceUncomplicated Plasmodium falciparum malariaDrug resistancePlasmodium falciparum malariaMalaria-endemic countriesPartner drug resistanceAdditional side effectsUncomplicated malariaFalciparum malariaTreatment optionsEndemic countriesPediatric diseasesSide effectsACT failureMalariaTherapyBurkina FasoFocus group discussionsEthical considerationsTreatmentQualitative studyStakeholder engagement activitiesSmall-quantity lipid-based nutrient supplements, with or without added zinc, do not cause excessive fat deposition in Burkinabe children: results from a cluster-randomized community trial
Abbeddou S, Jimenez E, Hess S, Somé J, Ouédraogo J, Brown K. Small-quantity lipid-based nutrient supplements, with or without added zinc, do not cause excessive fat deposition in Burkinabe children: results from a cluster-randomized community trial. European Journal Of Nutrition 2022, 61: 4107-4120. PMID: 35829783, PMCID: PMC9596589, DOI: 10.1007/s00394-022-02936-6.Peer-Reviewed Original ResearchConceptsSmall-quantity lipid-based nutrient supplementsNon-intervention cohortLipid-based nutrient supplementsIntervention cohortIntervention groupCluster-randomized community trialFat-free mass accretionAdditional zinc supplementationFat depositionTrial registrationThe studyCluster-randomized trial designDispersible tabletsMonths of ageExcessive fat depositionMorbidity treatmentNIC childrenNutrient supplementsBurkinabe childrenUS National InstitutesObesity riskZinc supplementationClinical trialsCommunity trialFat massTrial designEvaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings
Mulamba C, Williams C, Kreppel K, Ouedraogo J, Olotu A. Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings. Malaria Journal 2022, 21: 159. PMID: 35655174, PMCID: PMC9161629, DOI: 10.1186/s12936-022-04173-y.Peer-Reviewed Original ResearchConceptsEndemic settingsMalaria transmission-blocking vaccineHuman vaccine trialsTransmission-blocking vaccinesPublic health importanceMosquito vectorsMiddle-income settingsAnti-malarial drugsImmunological mechanismsCandidate vaccinesVaccine trialsHealthy individualsIncome settingsTransmission blockingHealth importanceMalaria controlMalaria parasitesVaccineLocal interventionsDrugsInterventionSettingSexual stagesPfs25DiseaseField evaluation of the diagnostic performance of EasyScan GO: a digital malaria microscopy device based on machine-learning
Das D, Vongpromek R, Assawariyathipat T, Srinamon K, Kennon K, Stepniewska K, Ghose A, Sayeed A, Faiz M, Netto R, Siqueira A, Yerbanga S, Ouédraogo J, Callery J, Peto T, Tripura R, Koukouikila-Koussounda F, Ntoumi F, Ong’echa J, Ogutu B, Ghimire P, Marfurt J, Ley B, Seck A, Ndiaye M, Moodley B, Sun L, Archasuksan L, Proux S, Nsobya S, Rosenthal P, Horning M, McGuire S, Mehanian C, Burkot S, Delahunt C, Bachman C, Price R, Dondorp A, Chappuis F, Guérin P, Dhorda M. Field evaluation of the diagnostic performance of EasyScan GO: a digital malaria microscopy device based on machine-learning. Malaria Journal 2022, 21: 122. PMID: 35413904, PMCID: PMC9004086, DOI: 10.1186/s12936-022-04146-1.Peer-Reviewed Original ResearchDelivery of seasonal malaria chemoprevention with enhanced infection prevention and control measures during the COVID-19 pandemic in Nigeria, Burkina Faso and Chad: a cross-sectional study
Ward C, Phillips A, Oresanya O, Olisenekwu G, Arogunade E, Moukénet A, Beakgoubé H, De Paul Allambademel V, Compaoré C, Traoré A, Ouedraogo J, Compaoré Y, Zongo I, Donovan L, Decola M, Smith H, Baker K. Delivery of seasonal malaria chemoprevention with enhanced infection prevention and control measures during the COVID-19 pandemic in Nigeria, Burkina Faso and Chad: a cross-sectional study. Malaria Journal 2022, 21: 103. PMID: 35331248, PMCID: PMC8943494, DOI: 10.1186/s12936-022-04091-z.Peer-Reviewed Original ResearchConceptsCross-sectional studyIPC measuresMalaria chemopreventionInfection preventionMethodsA cross-sectional studyEnhanced infection preventionSeasonal malaria chemopreventionCoronavirus disease 2019 (COVID-19) transmissionHigh malaria transmissionOptimal hand hygiene practicesHand hygiene practicesProportion of indicationsCOVID-19 pandemicEarly community engagementFirst doseHand hygieneWHO guidanceMalaria transmissionBurkina FasoHand washingControl measuresHygiene practicesProtective equipmentAdherenceBlister packsTemporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis
Dahal P, Simpson J, Abdulla S, Achan J, Adam I, Agarwal A, Allan R, Anvikar A, Arinaitwe E, Ashley E, Awab G, Bassat Q, Björkman A, Borrmann S, Bousema T, Bukirwa H, Carrara V, Corsi M, Cot M, D’Alessandro U, Davis T, Deloron P, Desai M, Dimbu P, Djalle D, Djimde A, Dorsey G, Drakeley C, Duparc S, Edstein M, Espie E, Faiz A, Falade C, Fanello C, Faucher J, Faye B, de Jesus Fortes F, Gadalla N, Gaye O, Gil J, Gilayeneh J, Greenwood B, Grivoyannis A, Hien T, Hwang J, Janssens B, Juma E, Kamugisha E, Karema C, Karunajeewa H, Kiechel J, Kironde F, Kofoed P, Kremsner P, Lee S, Marsh K, Mårtensson A, Mayxay M, Menan H, Mens P, Mutabingwa T, Ndiaye J, Ngasala B, Noedl H, Nosten F, Offianan A, Ogutu B, Olliaro P, Ouedraogo J, Piola P, Plowe C, Plucinski M, Pratt O, Premji Z, Ramharter M, Rogier C, Rombo L, Rosenthal P, Sibley C, Sirima S, Smithuis F, Staedke S, Sutanto I, Talisuna A, Tarning J, Taylor W, Temu E, Thriemer K, Thuy-Nhien N, Udhayakumar V, Ursing J, van Herp M, van Lenthe M, van Vugt M, William Y, Winnips C, Zaloumis S, Zongo I, White N, Guerin P, Stepniewska K, Price R. Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis. Malaria Journal 2022, 21: 106. PMID: 35331243, PMCID: PMC8943927, DOI: 10.1186/s12936-021-03980-z.Peer-Reviewed Original ResearchConceptsDihydroartemisinin-piperaquineDays follow-upFollow-upEfficacy trialsRecrudescent infectionsRisk of recrudescenceAnti-malarial efficacy studiesUncomplicated Plasmodium falciparum malariaArtemisinin-based combination therapyDuration of follow-upPlasmodium falciparum malariaAnti-malarial treatmentMethodsIndividual patient dataFollow-up periodFollow-up time pointsCox regression modelsClinical efficacy trialsTreatment Efficacy TrialData meta-analysisTrial follow-upMalaria recrudescencePiperaquine dosingRecrudescent parasitaemiaFalciparum malariaOptimal follow-up periodHaematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data
Mansoor R, Commons R, Douglas N, Abuaku B, Achan J, Adam I, Adjei G, Adjuik M, Alemayehu B, Allan R, Allen E, Anvikar A, Arinaitwe E, Ashley E, Ashurst H, Asih P, Bakyaita N, Barennes H, Barnes K, Basco L, Bassat Q, Baudin E, Bell D, Bethell D, Bjorkman A, Boulton C, Bousema T, Brasseur P, Bukirwa H, Burrow R, Carrara V, Cot M, D’Alessandro U, Das D, Das S, Davis T, Desai M, Djimde A, Dondorp A, Dorsey G, Drakeley C, Duparc S, Espié E, Etard J, Falade C, Faucher J, Filler S, Fogg C, Fukuda M, Gaye O, Genton B, Rahim A, Gilayeneh J, Gonzalez R, Grais R, Grandesso F, Greenwood B, Grivoyannis A, Hatz C, Hodel E, Humphreys G, Hwang J, Ishengoma D, Juma E, Kachur S, Kager P, Kamugisha E, Kamya M, Karema C, Kayentao K, Kazienga A, Kiechel J, Kofoed P, Koram K, Kremsner P, Lalloo D, Laman M, Lee S, Lell B, Maiga A, Mårtensson A, Mayxay M, Mbacham W, McGready R, Menan H, Ménard D, Mockenhaupt F, Moore B, Müller O, Nahum A, Ndiaye J, Newton P, Ngasala B, Nikiema F, Nji A, Noedl H, Nosten F, Ogutu B, Ojurongbe O, Osorio L, Ouédraogo J, Owusu-Agyei S, Pareek A, Penali L, Piola P, Plucinski M, Premji Z, Ramharter M, Richmond C, Rombo L, Roper C, Rosenthal P, Salman S, Same-Ekobo A, Sibley C, Sirima S, Smithuis F, Somé F, Staedke S, Starzengruber P, Strub-Wourgaft N, Sutanto I, Swarthout T, Syafruddin D, Talisuna A, Taylor W, Temu E, Thwing J, Tinto H, Tjitra E, Touré O, Tran T, Ursing J, Valea I, Valentini G, van Vugt M, von Seidlein L, Ward S, Were V, White N, Woodrow C, Yavo W, Yeka A, Zongo I, Simpson J, Guerin P, Stepniewska K, Price R. Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. BMC Medicine 2022, 20: 85. PMID: 35249546, PMCID: PMC8900374, DOI: 10.1186/s12916-022-02265-9.Peer-Reviewed Original ResearchConceptsUncomplicated P. falciparum malariaSevere anemiaDay 7Nadir hemoglobinParasite clearanceTreatment of uncomplicated P. falciparum malariaDay 3Risk factorsHaematological responseRate of parasite clearanceWorldWide Antimalarial Resistance NetworkArtemisinin-based regimensBackgroundPlasmodium falciparum malariaDelayed parasite clearanceMethodsIndividual patient dataMedian hemoglobin concentrationIndependent risk factorRisk of anemiaArtemisinin-based treatmentsDay 2 post treatmentDay of nadirModerately severe anemiaIndividual patient dataPatient dataMalarial anemia